Business
FDA panel knocks down Pfizer, Lilly’s osteoarthritis pain drug in near-unanimous vote – FierceBiotech
After dozens of trials over more than 15 years, Pfizer and Eli Lilly’s osteoarthritis hopeful was poised for an FDA decision in December 2020—that is, until the…
After dozens of trials over more than 15 years, Pfizer and Eli Lillys osteoarthritis hopeful was poised for an FDA decision in December 2020that is, until the agency called a panel of outside experts to chew over the drugs application. That panel came down against the drug in a vote on Thursday because of major safety risks and an inadequate plan to manage them.
The Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee voted 19-1 that a drug safety strategy proposed…
-
Noosa News23 hours agoHow Lily Steele-Park took her rapist to court and won
-
Noosa News24 hours agoE-biker charged with riding dangerously, assaulting cop
-
General22 hours agoBrick portico a relic of ‘prestigious’ Horton College in northern midlands
-
Business17 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today